A method to validate Next-generation sequencing (NGS) genotyping results of a panel of genes tested in a series of at least 2 patients characterized in that said validation is provided by SNP profiling assay, said method comprising the steps of: a) determining the genotype for a combination of at least 8 SNPs by an independent SNP profiling assay using the primary DNA samples used to obtain said NGS genotyping results, said NGS genotyping results including the genotype for said SNPs; b) comparing the SNPs genotypes obtained by said SNP profiling assay and NGS assay; c) validating or not NGS genotyping results based on said comparison, wherein: 1) If there are not two patients from the series with identical SNP profiles, and said SNPs genotypes obtained by said SNP profiling assay and said NGS assay are identical, then NGS genotyping results are validated; and 2) If two patients have identical SNP profiles but NGS genotyping results are distinct, a sequencing assay (e.g. Sanger sequencing) is further performed for these two patients, in order to validate their NGS genotyping results; and 3) In other cases, NGS genotyping results are not validated and further validation is necessary; wherein said SNPs have the following features: i. they are not located in a repeated sequence of the genome; ii. they are biallelic; iii. the 60 bases flanking sequences at either side of the SNP site has a GC content < 70% and an AT content <70%, iv. they are not associated to a known pathology. a) determining the genotype for a combination of at least 8 SNPs by an independent SNP profiling assay using the primary DNA samples used to obtain said NGS genotyping results, said NGS genotyping results including the genotype for said SNPs; b) comparing the SNPs genotypes obtained by said SNP profiling assay and NGS assay; c) validating or not NGS genotyping results based on said comparison, wherein: 1) If there are not two patients from the series with identical SNP profiles, and said SNPs genotypes obtained by said SNP profiling assay and said NGS assay are identical, then NGS genotyping results are validated; and 2) If two patients have identical SNP profiles but NGS genotyping results are distinct, a sequencing assay (e.g. Sanger sequencing) is further performed for these two patients, in order to validate their NGS genotyping results; and 3) In other cases, NGS genotyping results are not validated and further validation is necessary; 1) If there are not two patients from the series with identical SNP profiles, and said SNPs genotypes obtained by said SNP profiling assay and said NGS assay are identical, then NGS genotyping results are validated; and 2) If two patients have identical SNP profiles but NGS genotyping results are distinct, a sequencing assay (e.g. Sanger sequencing) is further performed for these two patients, in order to validate their NGS genotyping results; and 3) In other cases, NGS genotyping results are not validated and further validation is necessary; i. they are not located in a repeated sequence of the genome; ii. they are biallelic; iii. the 60 bases flanking sequences at either side of the SNP site has a GC content < 70% and an AT content <70%, iv. they are not associated to a known pathology. <EOS>